Oxycodone/Naloxone: Role in Chronic Pain Management, Opioid-Induced Constipation, and Abuse Deterrence

Pain and Therapy

Volumn 3, Issue 1, 2014, Pages 1-15

  DePriest, Anne Z ^a,b   Miller, Katie ^a,b  

^a Aegis Sciences Corporation   (United States)

^b UNIVERSITY OF TENNESSEE COLLEGE OF PHARMACY   (United States)

Author keywords

Abuse deterrent formulations; Chronic pain treatment; Opioid induced constipation; Opioids; Oxycodone naloxone

Indexed keywords

17 METHYLNALTREXONE; ALVIMOPAN; LAXATIVE; NALOXONE; NALOXONE PLUS OXYCODONE; OXYCODONE;

ANALGESIA; CANCER PAIN; CHRONIC PAIN; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MISUSE; GASTROINTESTINAL SYMPTOM; HUMAN; INTESTINE FUNCTION; PATIENT ASSESSMENT; PATIENT COMPLIANCE; PHARMACOECONOMICS; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SUSTAINED RELEASE FORMULATION;

EID: 84921525415     PISSN: 21938237     EISSN: 2193651X     Source Type: Journal    
DOI: 10.1007/s40122-014-0026-2     Document Type: Review

References (101)

1. Mercadante S. Prospects and challenges in opioid analgesia for pain management. Curr Med Res Opin. 2011;27(9):1741–3.
2. Gras B, Magge S, Bloom A, Lembo A. Motility disorders of the colon and rectum. Curr Opin Gastroenterol. 2013;29(1):66–71.
3. Sng BL, Schug SA. The role of opioids in managing chronic non-cancer pain. Ann Acad Med Singap. 2009;38(11):960–6.
4. Higginson IJ, Gao W. Opioid prescribing for cancer pain during the last 3 months of life: associated factors and 9-year trends in a nationwide United Kingdom cohort study. J Clin Oncol. 2012;30(35):4373–9.
5. Institute of Medicine (IOM). Relieving pain in America: a blueprint for transforming prevention, care, education, and research. Washington, DC: The National Academies Press; 2011.
6. Smith K, Hopp M, Mundin G, et al. Naloxone as part of a prolonged release oxycodone/naloxone combination reduces oxycodone-induced slowing of gastrointestinal transit in healthy volunteers. Expert Opin Investig Drugs. 2011;20(4):427–39.
7. Purdue Pharma. FDA accepts for review Purdue Pharma’s new drug application for Targiniq™ ER (oxycodone HCl/naloxone HCl controlled-release) tablets CII. Press release. 26 November 2013. http://www.purduepharma.com/news-media/2013/11/fda-accepts-for-review-purdue-pharmas-new-drug-application-for-targiniq-er-oxycodone-hclnaloxone-hcl-controlled-release-tablets-cii/. Accessed 2 Jan 2014.
8. Ballantyne JC. Opioid analgesia: perspectives on right use and utility. Pain Physician. 2007;10(3):479–91.
9. Clemens KE, Quednau I, Klaschik E. Bowel function during pain therapy with oxycodone/naloxone prolonged-release tablets in patients with advanced cancer. Int J Clin Pract. 2011;65(4):472–8.
10. Holzer P, Ahmedzai SH, Niederle N, et al. Opioid-induced bowel dysfunction in cancer-related pain: causes, consequences, and a novel approach for its management. J Opioid Manag. 2009;5(3):145–51.
11. Kurz A, Sessler DI. Opioid-induced bowel dysfunction: pathophysiology and potential new therapies. Drugs. 2003;63(7):649–71.
12. Woolery M, Bisanz A, Lyons HF, Gaido L, Yenulevich M, Fulton S, et al. Putting evidence into practice: evidence-based interventions for the prevention and management of constipation in patients with cancer. Clin J Oncol Nurs. 2008;12(2):317–37.
13. Meissner W, Leyendecker P, Mueller-Lissner S, et al. A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation. Eur J Pain. 2009;13(1):56–64.
14. Swegle JM, Logemann C. Management of common opioid-induced adverse effects. Am Fam Physician. 2006;74(8):1347–54.
15. Bell T, Annunziata K, Leslie JB. Opioid-induced constipation negatively impacts pain management, productivity, and health-related quality of life: findings from the National Health and Wellness Survey. J Opioid Manage. 2009;5(3):137–44.
16. Shook JE, Pelton JT, Hruby VJ, Burks TF. Peptide opioid antagonist separates peripheral and central opioid antitransit effects. J Pharmacol Exp Ther. 1987;243(2):492–500.
17. Wirz S, Wittmann M, Schenk M, et al. Gastrointestinal symptoms under opioid therapy: a prospective comparison of oral sustained-release hydromorphone, transdermal fentanyl, and transdermal buprenorphine. Eur J Pain. 2009;13(7):737–43.
18. Holzer P. Non-analgesic effects of opioids: management of opioid-induced constipation by peripheral opioid receptor antagonists: prevention or withdrawal? Curr Pharm Des. 2012;18(37):6010–20.
19. Reimer K, Hopp M, Zenz M, et al. Meeting the challenges of opioid-induced constipation in chronic pain management—a novel approach. Pharmacology. 2009;83(1):10–7.
20. Liu M, Wittbrodt E. Low-dose oral naloxone reverses opioid-induced constipation and analgesia. J Pain Symptom Manage. 2002;23(1):48–53.
21. Pappagallo M. Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg. 2001;182(5A Suppl):11S–8S.
22. Ishihara M, Ikesue H, Matsunaga H, et al. A multi-institutional study analyzing effect of prophylactic medication for prevention of opioid-induced gastrointestinal dysfunction. Clin J Pain. 2012;28(5):373–81.
23. Miles CL, Fellowes D, Goodman ML, Wilkinson S. Laxatives for the management of constipation in palliative care patients. Cochrane Database Syst Rev. 2006;(4):CD003448.
24. ®): Adult Cancer Pain. V 2.2013. http://www.nccn.org/professionals/physician_gls/pdf/pain.pdf. Accessed 2 Jan 2014.
25. Manara L, Bianchi G, Ferretti P, et al. Inhibition of gastrointestinal transit by morphine in rats results primarily from direct drug action on gut opioid sites. J Pharmacol Exp Ther. 1986;237(3):945–9.
26. Mori T, Shibasaki Y, Matsumoto K, et al. Mechanisms that underlie µ-opioid receptor agonist-induced constipation: differential involvement of µ-opioid receptor sites and responsible regions. J Pharmacol Exp Ther. 2013;347(1):91–9.
27. Parolaro D, Sala M, Gori E. Effect of intracerebroventricular administration of morphine upon intestinal motility in rate and its antagonism with naloxone. Eur J Pharmacol. 1977;46:329–38.
28. Stewart JJ, Weisbrodt NW, Burks TF. Central and peripheral actions of morphine on intestinal transit. J Pharmacol Exp Ther. 1978;205(3):547–55.
29. Porecca F, Cowan A, Raffa RB, et al. Ketazocines and morphine: effects on gastrointestinal transit after central and peripheral administration. Life Sci. 1983;32:1785–90.
30. Thorn SE, Wattwil M, Lindberg G, et al. Systemic and central effects of morphine on gastroduodenal motility. Acta Anaesthesiol Scand. 1996;40:177–86.
31. Iyer S, Davis KL, Candrilli S. Opioid use patterns and health care resource utilization in patients prescribed opioid therapy with and without constipation. Manag Care. 2010;19(3):44–51.
32. Kwong WJ, Diels J, Kavanagh S. Costs of gastrointestinal events after outpatient opioid treatment for non-cancer pain. Ann Pharmacother. 2010;44(4):630–40.
33. Gregorian RS Jr, Gasik A, Kwong WJ, Voeller S, Kavanagh S. Importance of side effects in opioid treatment: a trade-off analysis with patients and physicians. J Pain. 2010;11(11):1095–108.
34. Chou R, Fanciullo GJ, Fine PG, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009;10(2):113–30.
35. Tack J. Current and future therapies for chronic constipation. Best Pract Res Clin Gastroenterol. 2011;25(1):151–8.
36. Ford AC, Brenner DM, Schoenfeld PS. Efficacy of pharmacological therapies for the treatment of opioid-induced constipation: systematic review and meta-analysis. Am J Gastroenterol. 2013;108(10):1566–74; quiz 1575.
37. Holzer P. Opioid antagonists for prevention and treatment of opioid-induced gastrointestinal effects. Curr Opin Anaesthesiol. 2010;23(5):616–22.
38. Wyeth Pharmaceuticals Inc. Relistor. Prescribing information. Philadelphia: Wyeth Pharmaceuticals Inc.; 2010.
39. Yuan CS, Foss JF, O’Connor M, et al. Effects of enteric-coated methylnaltrexone in preventing opioid-induced delay in oral-cecal transit time. Clin Pharmacol Ther. 2000;67(4):398–404.
40. Yuan CS, Foss JF, O’Connor M, et al. Methylnaltrexone for reversal of constipation due to chronic methadone use: a randomized controlled trial. JAMA. 2000;283(3):367–72.
41. Cubist Pharmaceuticals, Inc. Entereg. Prescribing information. Lexington: Cubist Pharmaceuticals, Inc.; 2008.
42. Ahmedzai SH, Boland J. Constipation in people prescribed opioids. Clin Evid. 2010;04:2407.
43. Leppert W. The impact of opioid analgesics on the gastrointestinal tract function and the current management possibilities. Wspolczesna Onkol. 2012;16(2):125–31.
44. Weinstein SH, Pfeffer M, Schor JM, Indindoli L, Mintz M. Metabolites of naloxone in human urine. J Pharm Sci. 1971;60(10):1567–8.
45. Cubitt HE, Houston JB, Galetin A. Relative importance of intestinal and hepatic glucuronidation-impact on the prediction of drug clearance. Pharm Res. 2009;26(5):1073–83.
46. Napp Pharmaceuticals Limited. Targinact. Prescribing information. Cambridge: Napp Pharmaceuticals Limited; 2012.
47. Sykes NP. An investigation of the ability of oral naloxone to correct opioid-related constipation in patients with advanced cancer. Palliat Med. 1996;10(2):135–44.
48. Meissner W, Schmidt U, Hartmann M, Kath R, Reinhart K. Oral naloxone reverses opioid-associated constipation. Pain. 2000;84(1):105–9.
49. Kaufman PN, Krevsky B, Malmud LS, et al. Role of opiate receptors in the regulation of colonic transit. Gastroenterology. 1988;94(6):1351–6.
50. Smith K, Hopp M, Mundin G, et al. Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers. Clin Ther. 2008;30(11):2051–68.
51. Müller-Lissner S, Leyendecker P, Hopp M, Ruckes C, Fleischer W, Reimer K. Oral prolonged release (PR) oxycodone/naloxone combination reduces opioid-induced bowel dysfunction (OIBD) in patients with severe chronic pain. Eur J Pain. 2007;11(Suppl 1):S82.
52. Vondrackova D, Leyendecker P, Meissner W, et al. Analgesic efficacy and safety of oxycodone in combination with naloxone as prolonged release tablets in patients with moderate to severe chronic pain. J Pain. 2008;9(12):1144–54.
53. Simpson K, Leyendecker P, Hopp M, et al. Fixed-ratio combination oxycodone/naloxone compared with oxycodone alone for the relief of opioid-induced constipation in moderate-to-severe noncancer pain. Curr Med Res Opin. 2008;24(12):3503–12.
54. Löwenstein O, Leyendecker P, Hopp M, et al. Combined prolonged-release oxycodone and naloxone improves bowel function in patients receiving opioids for moderate-to-severe non-malignant chronic pain: a randomised controlled trial. Expert Opin Pharmacother. 2009;10(4):531–43.
55. Nadstawek J, Leyendecker P, Hopp M, et al. Patient assessment of a novel therapeutic approach for the treatment of severe, chronic pain. Int J Clin Pract. 2008;62(8):1159–67.
56. Ahmedzai SH, Nauck F, Bar-Sela G, Bosse B, Leyendecker P, Hopp M. A randomized, double-blind, active-controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain. Palliat Med. 2012;26(1):50–60.
57. Ueberall MA, Müller-Lissner S, Buschmann-Kramm C, Bosse B. The Bowel Function Index for evaluating constipation in pain patients: definition of a reference range for a non-constipated population of pain patients. J Int Med Res. 2011;39(1):41–50.
58. Rentz AM, Yu R, Müller-Lissner S, Leyendecker P. Validation of the Bowel Function Index to detect clinically meaningful changes in opioid-induced constipation. J Med Econ. 2009;12(4):371–83.
59. Foundation Rome. Guidelines—Rome III diagnostic criteria for functional gastrointestinal disorders. J Gastrointest Liver Dis. 2006;15(3):307–12.
60. Sandner-Kiesling A, Leyendecker P, Hopp M, et al. Long-term efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of non-cancer chronic pain. Int J Clin Pract. 2010;64(6):763–74.
61. Löwenstein O, Leyendecker P, Lux EA, et al. Efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of moderate/severe chronic non-malignant pain: results of a prospectively designed pooled analysis of two randomised, double-blind clinical trials. BMC Clin Pharmacol. 2010;10:12.
62. Cloutier C, Taliano J, O’Mahony W, et al. Controlled-release oxycodone and naloxone in the treatment of chronic low back pain: a placebo-controlled, randomized study. Pain Res Manag. 2013;18(2):75–82.
63. Kuusniemi K, Zollner J, Sjovall S, et al. Prolonged-release oxycodone/naloxone in postoperative pain management: from a randomized clinical trial to usual clinical practice. J Int Med Res. 2012;40(5):1775–93.
64. Davis M, Goforth HW, Gamier P. Oxycodone combined with opioid receptor antagonists: efficacy and safety. Expert Opin Drug Saf. 2013;12(3):389–402.
65. Lesaffre E. Superiority, equivalence, and non-inferiority trials. Bull NYU Hosp Jt Dis. 2008;66(2):150–4.
66. Schutter U, Grunert S, Meyer C, Schmidt T, Nolte T. Innovative pain therapy with a fixed combination of prolonged-release oxycodone/naloxone: a large observational study under conditions of daily practice. Curr Med Res Opin. 2010;26(6):1377–87.
67. Hermanns K, Junker U, Nolte T. Prolonged-release oxycodone/naloxone in the treatment of neuropathic pain—results from a large observational study. Expert Opin Pharmacother. 2012;13(3):299–311.
68. Cuomo A, Russo G, Esposito G, Forte CA, Connola M, Marcassa C. Efficacy and gastrointestinal tolerability of oral oxycodone/naloxone combination for chronic pain in outpatients with cancer: an observational study. Am J Hosp Palliat Care. 2013. (Epub ahead of print).
69. Lazzari M, Sabato AF, Caldarulo C, et al. Effectiveness and tolerability of low-dose oral oxycodone/naloxone added to anticonvulsant therapy for noncancer neuropathic pain: an observational analysis. Curr Med Res Opin. 2014;30(4):555–64.
70. Gatti A, Casali M, Lazzari M, et al. Prolonged-release oxycodone/naloxone in nonmalignant pain: single-center study in patients with constipation. Adv Ther. 2013;30(1):41–59.
71. Comelon M, Wisloeff-Aase K, Raeder J, et al. A comparison of oxycodone prolonged-release vs. oxycodone + naloxone prolonged-release after laparoscopic hysterectomy. Acta Anaesthesiol Scand. 2013;57(4):509–17.
72. Ruetzler K, Blome CJ, Nabecker S, et al. A randomised trial of oral versus intravenous opioids for treatment of pain after cardiac surgery. J Anesth. 2013. (Epub ahead of print).
73. Mercadante S, Ferrera P, Adile C. High doses of oxycodone-naloxone combination may provide poor analgesia. Support Care Cancer. 2011;19(9):1471–2.
74. Dunlop W, Uhl R, Khan I, Taylor A, Barton G. Quality of life benefits and cost impact of prolonged release oxycodone/naloxone versus prolonged release oxycodone in patients with moderate-to-severe non-malignant pain and opioid-induced constipation: a UK cost-utility analysis. J Med Econ. 2012;15(3):564–75.
75. Gálvez R, Provencio M, Sanz-Ortiz J, et al. Análisis económico de oxicodona LP/naloxona LP en el manejo del dolor intense y el estreñimiento asociado al tratamiento con opioids en España. Pharmacoeconomics – Spanish Research Articles. 2012;9(1):21–32.
76. Rychlik R, Kiencke P, Kresimon J. Health services research on HRQ oL and pharmacoeconomics of low back pain patients treated with oxycodone/naloxone or other Step III opioids. Gesundh ökon Qual Manag. 2011;16:S10–9.
77. Rychlik R, Viehmann K, Daniel D, Kiencke P, Kresimon J. Pain management and costs of a combination of oxycodone + naloxone in low back pain patients. In: Racz G (ed) Pain management—current issues and opinions. 2012. ISBN: 978-953-307-813-7. http://www.intechopen.com/books/pain-management-current-issues-and-opinions/pain-management-and-costs-of-a-combination-of-oxycodone-naloxone-in-low-back-pain-patients. Accessed 8 Feb 2014.
78. Gerlier L, Lamotte M, Van Megen Y. Treatment of moderate to severe pain with oxycodone/naloxone to reduce opioid-induced constipation: a cost-utility analysis in Belgium and the Netherlands (abstract PG115). Value Health. 2009;12(7):A348.
79. Australian Government Department of Health and Ageing Therapeutic Goods Administration. Australian Public Assessment Report for oxycodone hydrochloride/naloxone hydrochloride. Submission No: PM-2008-2938-1. May 2010. http://www.tga.gov.au/pdf/auspar/auspar-targin.pdf. Accessed 24 Dec 2013.
80. Ishihara M, Iihara H, Okayasu S, et al. Pharmaceutical interventions facilitate premedication and prevent opioid-induced constipation and emesis in cancer patients. Support Care Cancer. 2010;18(12):1531–8.
81. Leppert W. Oxycodone/naloxone in the management of patients with pain and opioid-induced bowel dysfunction. Curr Drug Targets. 2014;15(1):124–35.
82. Smith K, Hopp M, Mundin G, et al. Low absolute bioavailability of oral naloxone in healthy subjects. Int J Clin Pharmacol Ther. 2012;50(5):360–7.
83. Wilcock A. Prolonged-release naloxone can cause systemic opioid withdrawal. Eur J Pain. 2009;13(9):1001.
84. Compagnone C, Tagliaferri F, Ramelli A. Some concerns about the article: “High doses of oxycodone-naloxone combination may provide poor analgesia.”. Support Care Cancer. 2012;20(5):889–90.
85. Mercadante S. Clarifications on oxycodone-naloxone combination in cancer pain management. Support Care Cancer. 2012;20(7):1351–2.
86. Kang JH, Lee GW, Shin SH, Bruera E. Opioid withdrawal syndrome after treatment with low-dose extended-release oxycodone and naloxone in a gastric cancer patient with portal vein thrombosis. J Pain Symptom Manage. 2013;46(2):e15–7.
87. Trenkwalder C, Benes H, Grote L, et al. Prolonged release oxycodone-naloxone for treatment of severe restless legs syndrome after failure of previous treatment: a double-blind, randomised, placebo-controlled trial with an open-label extension. Lancet Neurol. 2013;12(12):1141–50.
88. Centers for Disease Control and Prevention (CDC). CDC grand rounds: prescription drug overdoses—a U.S. epidemic. MMWR Morb Mortal Wkly Rep. 2012;61(1):10–3.
89. Kirschner N, Ginsburg J, Sulmasy LS. Prescription drug abuse: a policy position paper from the American College of Physicians. Ann Intern Med. 2014;160(3):198.
90. Kirsh K, Peppin J, Coleman J. Characterization of prescription opioid abuse in the United States: focus on route of administration. J Pain Palliat Care Pharmacother. 2012;26(4):348–61.
91. Cicero TJ, Ellis MS, Surratt HL, Kurtz SP. Factors influencing the selection of hydrocodone and oxycodone as primary opioids in substance abusers seeking treatment in the United States. Pain. 2013;154(12):2639–48.
92. Cassidy TA, Dasmahapatra P, Black RA, Wieman MS, Butler SF. Changes in prevalence of prescription opioid abuse after introduction of an abuse-deterrent opioid formulation. Pain Med. 2014;15(3):440–51.
93. Mercadante S, Craig D, Giarratano A. US Food and Drug Administration’s Risk Evaluation and Mitigation Strategy for extended-release and long-acting opioids: pros and cons, and a European perspective. Drugs. 2012;72(18):2327–32.
94. Stanos SP. Strategies to reduce the tampering and subsequent abuse of long-acting opioids: potential risks and benefits of formulations with physical or pharmacologic deterrents to tampering. Mayo Clin Proc. 2012;87(7):683–94.
95. Coplan PM, Kale H, Sandstrom L, Landau C, Chilcoat HD. Changes in oxycodone and heroin exposures in the National Poison Data System after introduction of extended-release oxycodone with abuse-deterrent characteristics. Pharmacoepidemiol Drug Saf. 2013;22(12):1274–82.
96. Severtson SG, Bartelson BB, Davis JM, et al. Reduced abuse, therapeutic errors, and diversion following reformulation of extended-release oxycodone in 2010. J Pain. 2013;14(10):1122–30.
97. Tompkins DA, Lanier RK, Harrison JA, Strain EC, Bigelow GE. Human abuse liability assessment of oxycodone combined with ultra-low-dose naltrexone. Psychopharmacology. 2010;210(4):471–80.
98. Colucci S, Perrino P, Shram M, Bartlett C, Wang Y, Harris S. Abuse potential of oxycodone/naloxone solution administered intravenously in nondependent recreational drug users with moderate opioid experience (abstract). Presented at PAINWeek, September 2013. http://conference.painweek.org/media/mediafile_attachments/00/650-painweek2013acceptedabstracts.pdf. Accessed 6 Feb 2014.
99. Harris S, Perrino P, Shram M, Bartlett C, Colucci S, Wang Y. Abuse potential of oxycodone/naloxone (OXN) tablets administered intranasally in nondependent recreational drug users with moderate opioid experience (abstract). Presented at PAINWeek, September 2013. http://conference.painweek.org/media/mediafile_attachments/00/650-painweek2013acceptedabstracts.pdf. Accessed 6 Feb 2014.
100. Wang Y, Perrino P, Bartlett C, et al. Abuse potential of chewed or intact oxycodone/naloxone (OXN) tablets in methadone-stabilized, opioid-dependent subjects when administered orally (abstract). Presented at PAINWeek, September 2013. http://conference.painweek.org/media/mediafile_attachments/00/650-painweek2013acceptedabstracts.pdf. Accessed 6 Feb 2014.
101. Perrino P, Colucci S, Shram M, et al. Relative attractiveness of oxycodone/naloxone (OXN): comparative assessment of tampering potential and recreational drug user preferences for different opioid formulations (abstract). Presented at PAINWeek, September 2013. http://conference.painweek.org/media/mediafile_attachments/00/650-painweek2013acceptedabstracts.pdf. Accessed 6 Feb 2014.